Sign in

Blog · How-to guides · Pharmaceuticals

Pharmaceutical marketing analytics: measure campaign results

Pharmaceutical marketing analytics compares campaign costs, reach, and defined engagement across channels and territories. Work from approved aggregate exports, reconcile the audience and cost totals, and separate descriptive campaign results from prescribing or clinical claims.

The short answerPharmaceutical marketing analytics measures campaign spend, audience reach, and defined engagement by channel and territory. Use approved aggregate exports with consistent campaign windows, audience rules, and content versions. Calculate rates from comparable denominators and reconcile costs to finance. Engagement describes recorded interaction; it does not establish prescribing changes, clinical outcomes, or the incremental effect of promotion.

Pharmaceutical marketing analytics compares campaign cost, reach, and defined engagement across channels and territories using approved aggregate exports. It shows which audiences were reached, how they interacted, and what the recorded activity cost. Those observations do not establish prescribing effects or clinical outcomes.

Set the campaign question and its limits

A pharmaceutical marketing team needs to know whether a campaign reached its intended audience, whether that audience completed a defined action, and whether costs agree with the approved campaign register. Start with those questions rather than searching for a single score that blends unlike activities.

For an email campaign, engagement might mean an approved qualified click definition. For a webinar, it might mean attendance meeting a documented qualification rule. Opens, clicks, registrations, and attendance describe different stages. Keep the exact definition beside each result so that a change in measurement does not look like a change in audience response.

Campaign analytics also differs from field-force call-plan reporting. The existing reach and frequency guide for pharma sales teams covers targets called and calls against plan. This article covers aggregate campaign audiences, engagement, and spend; it does not rebuild that call-plan analysis.

Content review remains a separate responsibility. FDA's Office of Prescription Drug Promotion describes its role in reviewing prescription drug advertising and promotional labeling for false or misleading information. A campaign performance table does not establish that material is appropriate. Keep the company's approved content version and review status attached to the reporting scope.

Use approved aggregates with defined count units

The authorized data owner should prepare the export using the organization's eligibility, duplication, and disclosure rules. Use internally approved aggregate counts, excluding patient-level data and identifying HCP details. Small or sensitive groups should remain subject to the owner's disclosure review; the analyst should not attempt to reconstruct suppressed information.

The reporting table needs these columns:

Column Definition and control
Campaign and reporting window The activity being compared and its cutoff
Channel Email, webinar, or another separately defined activity
Territory The approved territory assignment for this campaign
Content version Internally approved material used for the activity
Eligible audience Distinct audience members eligible within that row
Reached audience Eligible audience members meeting the row's reach definition
Engaged audience Reached audience members meeting the engagement definition
Campaign cost (USD) Direct and allocated spend under one stated policy

For email, the example defines reach as at least one delivered campaign message. For webinars, reach means a registered eligible participant received the event access information. Engagement then means a qualified click or qualified attendance, respectively. These definitions make the denominator visible; they do not make the actions equivalent.

Use marketing research analytics when the question concerns audience attitudes or message understanding. Those questions require evidence beyond a delivery or interaction export.

A worked campaign comparison

Consider an illustrative US pharmaceutical company's internally approved HCP campaign report. North and South are mutually exclusive territory assignments. Counts are distinct within each territory-channel row, and the observation window is consistent within each channel. The same HCP may appear in both channels.

Territory Channel Cost (USD) Eligible Reached Engaged
North Email 8,000 2,000 1,600 320
South Email 6,300 1,500 1,050 210
North Webinar 12,000 800 400 160
South Webinar 9,000 600 300 90

The arithmetic is straightforward once the definitions are fixed:

Reach rate = Reached audience / Eligible audience

Engagement among reached = Engaged audience / Reached audience

Cost per engaged audience member = Campaign cost / Engaged audience

With the table in A:F and data in rows 2:5, calculate the measures in G:I:

G2 =IFERROR(E2/D2,"")
H2 =IFERROR(F2/E2,"")
I2 =IFERROR(C2/F2,"")

Fill down and review any blank result. Microsoft documents IFERROR as replacing formula errors with a specified value. Here a missing denominator stays blank for investigation rather than becoming an apparent zero rate. Covirage is not affiliated with Microsoft.

Territory and channel Reach rate Engagement among reached Cost per engaged audience member (USD)
North email 80.0% 20.0% 25.00
South email 70.0% 20.0% 30.00
North webinar 50.0% 40.0% 75.00
South webinar 50.0% 30.0% 100.00

Rates are rounded to one decimal place and costs to cents. North email's cost is 8,000 / 320 = $25.00. North webinar's cost is 12,000 / 160 = $75.00, but qualified attendance is a different action from a qualified click. The figures are useful for comparing territories within the same channel and definition; they do not rank those actions as interchangeable outcomes.

Roll up within a comparable channel

Because territory assignments are mutually exclusive, the territory counts can be added within each channel. Derive the combined rates from those totals.

Channel Cost (USD) Eligible Reached Engaged Reach rate Engagement among reached Cost per engaged (USD)
Email 14,300 3,500 2,650 530 75.7% 20.0% 26.98
Webinar 21,000 1,400 700 250 50.0% 35.7% 84.00

Email's cost per engaged audience member is 14,300 / 530 = $26.98. Webinar engagement among reached is 250 / 700 = 35.7%. Use summed costs and counts instead of averaging territory ratios.

If the detailed approved aggregate export contains several rows per channel, Microsoft's SUMIFS function sums values meeting specified criteria. For example, these formulas recover email spend and engaged counts from the first table:

=SUMIFS(C2:C5,B2:B5,"Email")
=SUMIFS(F2:F5,B2:B5,"Email")

Do not add the email and webinar audience counts and call the result unique reach. The supplied aggregates cannot resolve overlap between channels. Report channel counts separately unless the authorized source owner provides an independently deduplicated, approved cross-channel total.

Check the costs and decide what to investigate

Finance's campaign cost check is 14,300 + 21,000 = $35,300. That equals the detailed cost total of 8,000 + 6,300 + 12,000 + 9,000. Allocated creative or event costs must appear once, using the same policy across territories.

Marketing operations checks that engaged never exceeds reached and reached never exceeds eligible within a row. The campaign owner confirms that content versions, windows, and engagement rules match. These checks establish consistency, not promotional compliance or effectiveness.

South email has the same engagement rate as North email but higher cost per engagement. That directs a review toward cost allocation and delivery coverage before blaming the creative. The webinar comparison warrants a review of audience composition and attendance definitions. Neither conclusion establishes prescribing behavior. For the separate question of measured revenue versus marketing return, see marketing ROI versus ROAS.

Where it goes wrong

  • Adding unique audiences across channels. Overlapping audiences inflate a supposed campaign-wide reach count.
  • Different engagement actions under one heading. A click, registration, and qualified attendance need distinct labels.
  • Mismatched windows or content versions. Different exposure time or material can explain apparent territory differences.
  • Shared costs counted repeatedly. Reconcile channel and territory allocations to the campaign register.
  • Engagement presented as a prescribing effect. Recorded interaction supports descriptive findings, not causal or clinical claims.

Do this on your own file in Covirage

Bring internally approved aggregate campaign and cost exports with channel definitions, territory assignments, and reporting windows. Covirage maps the columns; its tools compute comparable rates and costs and check the totals, while the external AI model explains the results with every figure traced to its rows. Create a free Covirage account and bring a sample of your own approved export; creating an account takes about a minute.

See Covirage for pharmaceutical sales teams for the supporting industry context on HCP coverage.

Questions people ask

What does pharmaceutical marketing analytics measure?

It measures approved campaign activity such as eligible audiences, reached audiences, defined engagement, and cost by channel or territory. The useful output states the count unit and reporting window. It does not turn a click or attendance record into evidence of prescribing behavior.

Can email clicks and webinar attendance be combined?

They can appear in one reporting pack, but keep their definitions and denominators separate. A click and a qualified attendance are different actions. Audiences may also overlap across channels, so adding channel-level unique counts does not produce a unique campaign audience.

What data is appropriate for pharmaceutical campaign analysis?

Use internally approved aggregate exports containing campaign codes, channel, territory, content version, audience counts, engagement counts, and allocated costs. Exclude patient-level records and identifying details. Have the authorized data owner apply eligibility, duplication, and suppression rules before preparing the analysis file.

Does higher campaign engagement imply more prescriptions?

No. Engagement records show interaction under a chosen definition. They do not establish a prescribing effect or clinical benefit. Audience selection, channel design, access conditions, and other activity may differ. Keep commercial outcome studies separate and use conclusions supported by their design.